Article

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern

2021-11-09

Abstract excerpt

The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here we confirm that neutralizing and binding responses to Ad26.COV2.S vaccination are stable for 6 months post-vaccination, when tested against multiple SARS-CoV-2 variants. Secondly, using longitudinal samples from individuals who experienced cl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 391dced4-239e-549d-8b3e-c9dda0998ecc
DOI: 10.1101/2021.11.08.21266049

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concernDOI 10.1101/2021.11.08.21266049Read

Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients.Semantic proximity Read

Employment of a high-throughput functional assay to define the critical factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2.Semantic proximity Read

COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicronSemantic proximity Read

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccinationSemantic proximity Read

Potent cross-reactive antibodies following Omicron breakthrough in vaccineesSemantic proximity Read

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responsesSemantic proximity Read

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responsesSemantic proximity Read

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variantsSemantic proximity Read

Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipientsSemantic proximity Read

Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity Read

SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3<sup>rd</sup> mRNA Vaccine DoseSemantic proximity Read

mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concernSemantic proximity Read